ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
37 hedge funds and large institutions have $42.6M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
19% more funds holding
Funds holding: 31 → 37 (+6)
52% less capital invested
Capital invested by funds: $88.2M → $42.6M (-$45.6M)
95% less call options, than puts
Call options by funds: $32K | Put options by funds: $596K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.77M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$711K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$711K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$638K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$548K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.6M |
| 2 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$3.94M |
| 3 |
O
OrbiMed
New York
|
-$1.56M |
| 4 |
Goldman Sachs
New York
|
-$1.09M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$745K |
ASLN Hedge Fund Activity: Q3 2021 in Review
37 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q3 2021, worth a combined $42.6M — down 52% from $88.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ASLN positions and 6 closed out — a net gain of 6 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $2.77M. The largest seller was Logos Global Management, exiting entirely with an estimated $6.6M sold.
- 37 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q3 2021, up from 31 in Q2 2021.
- Funds reported $42.6M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q3 2021, down 52% quarter-over-quarter.
- 12 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q3 2021 and 6 closed out, a net change of +6 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q3 2021 was Tang Capital Management, an estimated $2.77M added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q3 2021 was Logos Global Management, an estimated $6.6M sold.
Based on aggregated 13F filings for Q3 2021.